{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:05:21Z","timestamp":1792854321065,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10147-020-01656-3","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T08:02:33Z","timestamp":1585209753000},"page":"1291-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II study of 5-fluorouracil\u2013leucovorin plus bevacizumab for chemotherapy-na\u00efve older or frail patients with metastatic colorectal cancer (OGSG 0802)"],"prefix":"10.1007","volume":"25","author":[{"given":"Takashi","family":"Ohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyoshi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Otsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tsujie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"1656_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"1656_CR2","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: as randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"1656_CR3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase iii study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407g). Ann Oncol 27:1539\u20131546","journal-title":"Ann Oncol"},{"key":"1656_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"1656_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"key":"1656_CR6","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","volume":"36","author":"S Qin","year":"2018","unstructured":"Qin S, Li J, Wang L et al (2018) Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with ras wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol 36:3031\u20133039","journal-title":"J Clin Oncol"},{"key":"1656_CR7","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"LS Schwartzberg","year":"2014","unstructured":"Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type kras exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240\u20132247","journal-title":"J Clin Oncol"},{"key":"1656_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J et al (2014) Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25:1346\u20131355","journal-title":"Ann Oncol"},{"key":"1656_CR9","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"1656_CR10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315","journal-title":"Lancet Oncol"},{"key":"1656_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"1656_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.dld.2016.05.011","volume":"48","author":"T Aparicio","year":"2016","unstructured":"Aparicio T, Pamoukdjian F, Quero L et al (2016) Colorectal cancer care in elderly patients: Unsolved issues. Dig Liver Dis 48:1112\u20131118","journal-title":"Dig Liver Dis"},{"key":"1656_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clcc.2015.12.001","volume":"15","author":"T Nishina","year":"2016","unstructured":"Nishina T, Moriwaki T, Shimada M et al (2016) Uracil-tegafur and oral leucovorin combined with bevacizumab in elderly patients (aged %3e\/= 75 years) with metastatic colorectal cancer: a multicenter, phase II trial (joint study of bevacizumab, oral leucovorin, and uracil-tegafur in elderly patients [J-BLUE] study). Clin Colorectal Cancer 15:236\u2013242","journal-title":"Clin Colorectal Cancer"},{"key":"1656_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077\u20131085","journal-title":"Lancet Oncol"},{"key":"1656_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.18.00052","volume":"37","author":"DP Modest","year":"2019","unstructured":"Modest DP, Weikersthal LF, Decker T et al (2019) Sequential versus combination therapy of metastatic colorectal cancer using fluoropyrimidines, irinotecan, and bevacizumab: a randomized, controlled study-XELAVIRI (AIO KRK0110). J Clin Oncol 37:22\u201332","journal-title":"J Clin Oncol"},{"key":"1656_CR16","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697\u20133705","journal-title":"J Clin Oncol"},{"key":"1656_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60\u201365","journal-title":"J Clin Oncol"},{"key":"1656_CR18","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706\u20133712","journal-title":"J Clin Oncol"},{"key":"1656_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.critrevonc.2009.02.006","volume":"72","author":"MW Saif","year":"2009","unstructured":"Saif MW, Lichtman SM (2009) Chemotherapy options and outcomes in older adult patients with colorectal cancer. Crit Rev Oncol Hematol 72:155\u2013169","journal-title":"Crit Rev Oncol Hematol"},{"key":"1656_CR20","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2004.05.017","volume":"22","author":"K Shirao","year":"2004","unstructured":"Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil\/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: Joint United States and Japan study of UFT\/LV. J Clin Oncol 22:3466\u20133474","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-020-01656-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:48:56Z","timestamp":1616719736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-020-01656-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01656-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]},"assertion":[{"value":"14 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Ohta has received lecture fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co. Ltd., and Teijin Pharma Ltd., T. Kato has received honoraria from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bayer Yakuhin Ltd., Sanofi K.K., Yakult Honsha Co. Ltd., and research funding from Chugai Pharmaceutical Co. Ltd., H. Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd; honoraria from Bristol-Myers Squibb Co. Ltd., AstraZeneca K.K., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd., lecture fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd., and research funding from Chugai Pharmaceutical Co. Ltd. and Eisai Co. Ltd., M. Nakamura. has received honoraria from Chugai Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Yakult Honsha Co. Ltd., Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Sanofi K.K., Bayer Yakuhin Ltd., and Otsuka Pharmaceutical Co. Ltd., N. Sugimoto has received research funding from MSD K.K., Ono Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Daiichi Sankyo Co. Ltd., M. Kotaka has received honoraria from Chugai Pharmaceutical Co. Ltd., Yakult Honsha Co. Ltd., Kaken Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bayer Yakuhin Ltd., and Sanofi K.K. H. Mishima has received honoraria and research funding from Chugai Pharmaceutical Co. Ltd., T. Hata has received lecture fees from Daiichi Sankyo Co. Ltd., T. Satoh received research grants from Giliad; consulting fees from Daiichi Sankyo and Takeda Pharmaceutical, Co. Ltd.; consulting fees, honoraria and research grants from Merck BioPharm, Bristol-Myers K.K., Taiho pharmaceutical, Elli Lilly, MSD,, Sanofi, Bristol Myers-Squib; and departmental research grants, research grants, honoraria and consulting fees from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical. Co. Ltd. and Yakult Honsha Co. Ltd. Y. Miyake, M. Goto, S. Iwamoto, T. Otsuji, S. Okumura, M. Tsujie, Y. Tokunaga, T. Shimokawa and Y. Kurokawa have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}